▁British 10.375
▁Bi 10.875
ote 5.59765625
ch 4.53515625
' 7.3671875
s 1.04296875
▁Can 5.2890625
cer 1.43359375
▁D 4.6640625
rug 3.82421875
▁Sh 8.015625
ows 3.69140625
▁Pos 8.1796875
itive 1.9873046875
▁Results 4.9609375
▁but 9.421875
▁Anal 9.09375
yst 3.064453125
s 1.50390625
▁Ur 8.671875
ge 2.798828125
▁Ca 5.828125
ution 0.0860595703125
<0x0A> 4.078125
L 5.02734375
ON 4.63671875
D 0.002902984619140625
ON 0.00016129016876220703
▁— 2.89453125
▁British 4.13671875
▁bi 4.3984375
ote 0.1455078125
chn 1.7236328125
ology 0.017242431640625
▁company 0.5927734375
, 3.380859375
▁Med 4.4765625
Cell 9.4453125
▁Th 3.0
era 0.00026535987854003906
pe 0.001300811767578125
ut 0.0004856586456298828
ics 0.007091522216796875
, 0.69482421875
▁announced 2.546875
▁positive 5.5390625
▁results 0.491943359375
▁in 2.798828125
▁their 3.013671875
▁latest 2.833984375
▁clin 1.2646484375
ical 0.001392364501953125
▁trial 0.279296875
▁for 2.716796875
▁their 1.91796875
▁innov 5.53515625
ative 0.0263824462890625
▁cancer 4.078125
▁drug 2.171875
, 0.7744140625
▁On 6.51171875
col 1.9736328125
yn 5.52734375
, 1.41015625
▁yesterday 5.921875
. 0.43505859375
▁The 1.0087890625
▁drug 2.478515625
' 4.19140625
s 0.000972747802734375
▁encourag 7.01953125
ing 0.00617218017578125
▁performance 3.83203125
▁in 1.6767578125
▁tre 2.67578125
ating 0.0002696514129638672
▁advanced 3.37890625
▁forms 4.62890625
▁of 0.00885772705078125
▁lung 2.578125
▁cancer 0.103271484375
, 2.21875
▁combined 4.609375
▁with 0.009979248046875
▁its 1.9736328125
▁relatively 5.16796875
▁low 0.50048828125
▁side 2.177734375
▁effects 0.68505859375
, 0.396484375
▁have 2.587890625
▁generated 4.609375
▁considerable 2.998046875
▁excitement 1.482421875
▁among 1.7958984375
▁do 3.4921875
ctors 0.0008258819580078125
▁and 0.4951171875
▁patients 1.185546875
▁al 0.8427734375
ike 5.161762237548828e-05
. 0.1871337890625
▁However 4.30078125
, 0.0264434814453125
▁anal 4.62890625
yst 0.00646209716796875
s 0.0089263916015625
▁are 2.029296875
▁ur 2.787109375
ging 0.007747650146484375
▁ca 0.052001953125
ution 0.0002949237823486328
, 1.0498046875
▁as 1.140625
ser 6.90625
ting 0.0003998279571533203
▁that 0.077880859375
▁further 3.41015625
▁investigation 3.841796875
▁is 0.50732421875
▁required 1.4306640625
▁before 1.17578125
▁definit 5.8359375
ive 0.1243896484375
▁conclus 0.30712890625
ions 0.0009908676147460938
▁can 0.1446533203125
▁be 0.0027446746826171875
▁drawn 0.57177734375
▁about 2.216796875
▁the 0.4384765625
▁drug 0.5341796875
' 0.13232421875
s 0.00022304058074951172
▁effic 1.4140625
acy 0.00016129016876220703
▁and 1.791015625
▁long 3.619140625
- 0.20458984375
term 0.004024505615234375
▁effects 1.7001953125
. 0.30029296875
<0x0A> 0.1942138671875
In 3.826171875
▁the 1.1015625
▁phase 7.0234375
▁II 1.9716796875
▁clin 1.0693359375
ical 0.0010538101196289062
▁trial 0.0274505615234375
, 0.2154541015625
▁On 2.232421875
col 0.0091705322265625
yn 0.0009264945983886719
▁exhib 7.19921875
ited 0.003757476806640625
▁prom 2.564453125
ising 0.0004017353057861328
▁out 5.0
comes 0.0030364990234375
▁in 0.55810546875
▁patients 2.873046875
▁with 0.50341796875
▁stage 3.99609375
▁IV 0.54296875
▁non 0.99951171875
- 0.040771484375
small 0.00875091552734375
▁cell 0.0914306640625
▁lung 0.01165008544921875
▁cancer 0.027435302734375
▁( 1.3251953125
NS 0.0260162353515625
CLC 0.00852203369140625
). 0.998046875
▁The 1.166015625
▁study 2.6015625
▁involved 3.06640625
▁ 0.6357421875
3 2.248046875
5 2.498046875
0 3.025390625
▁patients 0.2451171875
▁who 2.087890625
▁were 0.64892578125
▁random 3.16796875
ized 0.0310821533203125
▁to 0.78662109375
▁receive 0.61083984375
▁either 0.236083984375
▁On 1.1455078125
col 0.008453369140625
yn 0.0008759498596191406
▁or 0.439697265625
▁a 1.0322265625
▁place 0.1827392578125
bo 0.0021800994873046875
▁in 2.53515625
▁combination 2.83984375
▁with 0.060546875
▁standard 2.45703125
▁chem 1.291015625
other 0.02862548828125
apy 0.0297698974609375
. 0.431884765625
▁Although 4.98828125
▁specific 7.07421875
▁data 2.333984375
▁on 1.7939453125
▁patient 4.07421875
▁out 0.492919921875
comes 0.0006051063537597656
▁have 3.060546875
▁not 0.4609375
▁been 0.98828125
▁dis 3.455078125
closed 0.039031982421875
, 0.294921875
▁Med 3.373046875
Cell 0.0075225830078125
▁reported 3.916015625
▁that 0.3388671875
▁On 2.69140625
col 0.004734039306640625
yn 0.0004906654357910156
▁demonstrated 3.015625
▁a 0.9169921875
▁statist 1.5009765625
ically 0.0004394054412841797
▁significant 0.055419921875
▁improvement 1.193359375
▁in 0.215576171875
▁overall 1.42578125
▁response 2.859375
▁rate 0.56396484375
▁and 2.15625
▁pro 1.5322265625
gression 0.002105712890625
- 0.1572265625
free 0.001621246337890625
▁surv 0.017547607421875
ival 0.0004673004150390625
, 1.8828125
▁compared 2.068359375
▁to 0.25390625
▁the 1.0107421875
▁control 1.8876953125
▁group 0.233154296875
. 0.222900390625
<0x0A> 1.0947265625
Dr 3.63671875
. 0.0487060546875
▁Elizabeth 6.37109375
▁Thompson 6.0703125
, 0.114990234375
▁a 1.498046875
▁ren 5.5390625
owned 0.004871368408203125
▁on 0.9208984375
colog 0.183837890625
ist 0.0192718505859375
▁at 1.2939453125
▁The 3.93359375
▁Royal 1.865234375
▁Mars 0.2308349609375
den 0.002948760986328125
▁Hospital 0.625
, 0.826171875
▁expressed 3.12109375
▁her 1.150390625
▁enthus 1.984375
ias 0.01337432861328125
m 0.00010967254638671875
▁regarding 2.869140625
▁these 4.16796875
▁inter 8.953125
im 0.0136260986328125
▁find 1.564453125
ings 7.748603820800781e-06
. 0.654296875
▁" 0.2005615234375
The 1.9794921875
▁pre 5.0234375
lim 0.015869140625
inary 0.00238037109375
▁results 0.5068359375
▁of 1.87109375
▁this 0.42578125
▁trial 1.0068359375
▁are 0.377197265625
▁genu 7.42578125
in 0.009796142578125
ely 4.6372413635253906e-05
▁exc 1.3046875
iting 3.731250762939453e-05
. 1.1904296875
▁To 5.18359375
▁witness 3.65625
▁a 1.9443359375
▁new 2.291015625
▁drug 0.84375
▁show 4.0078125
▁such 0.5966796875
▁potential 5.63671875
▁in 0.8466796875
▁an 4.1171875
▁ag 3.609375
gress 0.0006136894226074219
ive 0.0121307373046875
▁form 0.67529296875
▁of 0.0017004013061523438
▁cancer 0.479248046875
▁like 3.39453125
▁NS 1.03515625
CLC 0.007568359375
▁is 0.33984375
▁an 3.2890625
▁incred 1.271484375
ible 0.216796875
▁step 4.6171875
▁forward 0.212158203125
▁in 0.95751953125
▁the 0.7373046875
▁search 3.69921875
▁for 0.019500732421875
▁more 3.240234375
▁effective 0.11590576171875
▁treat 1.212890625
ments 4.9114227294921875e-05
," 2.326171875
▁she 0.501953125
▁said 0.407958984375
. 0.1007080078125
▁L 9.84375
ung 0.45947265625
▁cancer 0.054351806640625
, 2.490234375
▁she 3.986328125
▁noted 2.720703125
, 0.008758544921875
▁is 0.484375
▁the 1.1533203125
▁leading 1.068359375
▁cause 0.03863525390625
▁of 0.00185394287109375
▁cancer 0.185302734375
▁death 1.076171875
s 0.572265625
▁world 1.1015625
wide 0.006778717041015625
, 0.544921875
▁thus 7.53125
▁any 3.533203125
▁adv 2.646484375
ances 0.73876953125
▁in 0.53564453125
▁its 1.93359375
▁treatment 0.1541748046875
▁are 0.58349609375
▁greatly 3.626953125
▁anticip 3.740234375
ated 3.8743019104003906e-05
. 0.1314697265625
<0x0A> 0.253662109375
However 1.60546875
, 0.00450897216796875
▁ca 6.8515625
ution 0.0098419189453125
▁is 1.3310546875
▁war 2.091796875
r 0.00041484832763671875
anted 4.267692565917969e-05
, 1.3427734375
▁given 2.94921875
▁the 0.54638671875
▁pre 4.48828125
lim 0.111328125
inary 0.00415802001953125
▁nature 0.401123046875
▁of 0.004749298095703125
▁these 1.49609375
▁results 0.78271484375
. 0.213623046875
▁Anal 3.75
yst 0.0016508102416992188
s 0.01186370849609375
▁emphas 3.955078125
ize 0.9384765625
▁the 1.203125
▁need 0.9013671875
▁for 0.11279296875
▁additional 1.9716796875
▁data 3.03125
▁from 2.310546875
▁a 2.248046875
▁larger 0.331787109375
, 1.796875
▁random 1.765625
ized 0.0046539306640625
, 1.4404296875
▁phase 2.822265625
▁III 0.0147857666015625
▁clin 1.05859375
ical 0.0002522468566894531
▁trial 0.0214691162109375
▁to 1.8779296875
▁cor 5.05078125
ro 0.0001671314239501953
bor 0.00019633769989013672
ate 0.0001939535140991211
▁the 0.630859375
▁initial 2.76953125
▁find 0.5771484375
ings 8.106231689453125e-06
. 0.28759765625
▁Ob 8.40625
ser 0.1326904296875
vers 0.06597900390625
▁have 3.052734375
▁pointed 4.44921875
▁out 0.326904296875
▁that 0.214111328125
▁several 5.1171875
▁cancer 6.32421875
▁dru 0.498779296875
gs 3.814697265625e-06
▁in 3.630859375
▁the 1.12890625
▁past 1.1787109375
▁have 0.291259765625
▁demonstrated 2.869140625
▁encourag 2.634765625
ing 0.0011997222900390625
▁results 0.94677734375
▁in 0.153076171875
▁phase 2.052734375
▁II 0.1650390625
▁tri 0.6982421875
als 1.0013580322265625e-05
▁but 1.7275390625
▁failed 1.080078125
▁to 0.0302276611328125
▁gain 4.81640625
▁regul 2.390625
atory 0.00043964385986328125
▁appro 0.0234832763671875
val 5.078315734863281e-05
▁due 2.478515625
▁to 0.0164642333984375
▁ins 2.080078125
u 0.00327301025390625
fficient 0.0018405914306640625
▁effic 2.744140625
acy 5.805492401123047e-05
▁or 1.841796875
▁un 3.275390625
for 3.1796875
ese 0.0081024169921875
en 0.0185394287109375
▁side 0.6142578125
▁effects 0.03167724609375
▁in 3.08203125
▁further 4.390625
▁studies 1.580078125
. 0.0382080078125
<0x0A> 0.75634765625
More 5.265625
over 0.7109375
, 0.0006327629089355469
▁the 1.7568359375
▁long 4.83203125
- 0.034393310546875
term 0.0036258697509765625
▁effects 0.54541015625
▁of 0.06683349609375
▁On 0.58349609375
col 0.0033664703369140625
yn 0.0005249977111816406
, 2.634765625
▁especially 3.30078125
▁in 1.259765625
▁terms 3.2421875
▁of 0.0007834434509277344
▁surv 4.94140625
ival 0.0161895751953125
▁rates 1.2431640625
, 0.255615234375
▁remain 2.3046875
▁unknown 1.146484375
. 0.2337646484375
▁Additionally 5.0859375
, 0.0011644363403320312
▁the 1.0927734375
▁phase 6.40234375
▁II 0.81298828125
▁trial 0.50244140625
▁only 2.275390625
▁involved 1.6455078125
▁patients 1.3837890625
▁with 0.53125
▁advanced 0.60009765625
▁NS 1.185546875
CLC 0.001953125
, 0.5771484375
▁limit 4.65625
ing 2.6106834411621094e-05
▁the 0.77099609375
▁drug 2.09765625
' 0.0098419189453125
s 3.3974647521972656e-05
▁potential 0.79345703125
▁impact 3.130859375
▁on 0.2288818359375
▁other 1.2451171875
▁tum 5.59375
or 0.09503173828125
▁types 0.0214385986328125
. 0.5205078125
▁Further 3.60546875
▁research 1.205078125
▁needs 5.33203125
▁to 0.004634857177734375
▁be 0.125732421875
▁conducted 0.54150390625
▁to 0.60888671875
▁as 3.501953125
certain 9.906291961669922e-05
▁the 1.0380859375
▁drug 0.6552734375
' 0.0008182525634765625
s 0.0003516674041748047
▁effic 1.16796875
acy 3.135204315185547e-05
▁in 0.603515625
▁other 1.275390625
▁forms 1.1494140625
▁of 0.006805419921875
▁lung 2.171875
▁cancer 0.01110076904296875
▁and 1.134765625
▁different 7.51171875
▁stages 1.865234375
▁of 0.0300750732421875
▁disease 1.2744140625
▁pro 1.1748046875
gression 0.0002651214599609375
. 0.18115234375
<0x0A> 0.41748046875
Des 3.1875
p 0.0080413818359375
ite 6.902217864990234e-05
▁the 1.685546875
▁res 6.5
erv 0.016143798828125
ations 1.52587890625e-05
, 1.3115234375
▁financial 8.6484375
▁mark 3.35546875
ets 0.003910064697265625
▁have 1.0302734375
▁respond 1.9912109375
ed 0.0001823902130126953
▁posit 0.2890625
ively 5.6624412536621094e-05
▁to 0.074462890625
▁Med 2.646484375
Cell 0.0034503936767578125
▁Th 1.4560546875
era 0.00011539459228515625
pe 3.9458274841308594e-05
ut 0.0006246566772460938
ics 0.00592803955078125
' 0.1251220703125
▁announ 2.037109375
cement 0.0037899017333984375
, 2.048828125
▁with 0.51806640625
▁the 0.79248046875
▁company 0.97412109375
' 0.042022705078125
s 0.0001697540283203125
▁stock 0.68603515625
▁so 3.853515625
aring 0.0038700103759765625
▁by 1.365234375
▁almost 3.396484375
▁ 0.08038330078125
3 2.0546875
0 0.311279296875
%. 2.322265625
▁In 2.490234375
vest 0.5625
ors 0.07733154296875
▁are 1.02734375
▁bu 4.06640625
oy 0.5263671875
ed 0.0697021484375
▁by 0.0181732177734375
▁the 0.3330078125
▁potential 2.701171875
▁of 0.951171875
▁On 1.10546875
col 0.0022029876708984375
yn 0.0004470348358154297
▁to 2.044921875
▁dis 5.16796875
rupt 0.1580810546875
▁the 0.28564453125
▁lung 2.779296875
▁cancer 0.0096282958984375
▁treatment 0.5068359375
▁landscape 1.8466796875
, 0.68701171875
▁which 1.9599609375
▁is 1.1875
▁anticip 8.234375
ated 0.00617218017578125
▁to 0.00800323486328125
▁reach 2.578125
▁a 2.4375
▁market 1.546875
▁value 0.71484375
▁of 0.0292510986328125
▁$ 0.8603515625
2 1.7236328125
0 1.8505859375
▁billion 0.410400390625
▁by 0.19873046875
▁ 0.05712890625
2 2.1576881408691406e-05
0 0.0001323223114013672
2 0.308837890625
4 2.64453125
. 0.284912109375
<0x0A> 0.69775390625
Med 2.572265625
Cell 0.03570556640625
▁CE 5.22265625
O 0.00023758411407470703
, 0.51953125
▁Dr 1.6044921875
. 0.01480865478515625
▁Jonathan 4.88671875
▁Reyn 6.9765625
olds 0.1258544921875
, 0.048187255859375
▁emb 9.359375
rac 0.4482421875
ed 0.00467681884765625
▁the 0.2445068359375
▁positive 1.6171875
▁reception 2.8359375
▁but 6.76953125
▁acknowled 3.16796875
ged 0.0037670135498046875
▁the 0.68603515625
▁work 6.81640625
▁that 1.0537109375
▁lies 1.765625
▁ahead 0.00864410400390625
. 0.403076171875
▁" 0.07501220703125
We 1.24609375
▁are 0.82861328125
▁encourag 2.2578125
ed 0.0005950927734375
▁by 0.04931640625
▁the 0.450439453125
▁initial 1.8017578125
▁results 0.6376953125
▁of 1.0166015625
▁the 1.6982421875
▁On 2.185546875
col 0.00250244140625
yn 0.0012063980102539062
▁trial 1.7919921875
▁and 1.666015625
▁their 5.0390625
▁potential 0.97998046875
▁imp 3.171875
lications 0.038116455078125
▁for 0.34765625
▁cancer 2.396484375
▁patients 0.79150390625
▁around 2.28515625
▁the 0.0001583099365234375
▁world 0.06512451171875
. 0.51953125
▁However 0.78369140625
, 0.0034637451171875
▁we 0.8525390625
▁understand 4.796875
▁that 0.385009765625
▁the 2.1796875
▁journey 5.94921875
▁to 1.2744140625
▁regul 3.26171875
atory 0.0002446174621582031
▁appro 0.0182647705078125
val 3.62396240234375e-05
▁is 0.796875
▁a 1.5439453125
▁rig 7.01953125
orous 0.0009407997131347656
▁one 0.454345703125
, 0.73583984375
▁and 0.2154541015625
▁we 0.39501953125
▁remain 2.240234375
▁committed 0.62646484375
▁to 0.0028934478759765625
▁further 3.36328125
▁expl 2.51953125
oring 0.2457275390625
▁the 0.5068359375
▁safety 5.28515625
▁and 0.08660888671875
▁effic 0.074462890625
acy 1.4901161193847656e-05
▁of 0.040985107421875
▁On 1.0556640625
col 0.0009355545043945312
yn 0.00041794776916503906
▁in 0.439208984375
▁larger 2.830078125
▁clin 1.5068359375
ical 0.00014209747314453125
▁studies 2.244140625
," 1.046875
▁he 0.075439453125
▁stated 2.994140625
, 4.60546875
▁highlight 5.703125
ing 0.000469207763671875
▁the 0.294921875
▁company 1.9853515625
' 0.0009102821350097656
s 0.0002346038818359375
▁commit 1.484375
ment 0.0008363723754882812
▁to 0.0205535888671875
▁a 5.53515625
▁thorough 4.24609375
▁and 2.267578125
▁compreh 2.12109375
ensive 0.00014972686767578125
▁evaluation 1.802734375
▁of 0.2098388671875
▁the 0.405517578125
▁drug 0.13671875
' 0.4189453125
s 0.0004417896270751953
▁potential 1.044921875
. 0.9716796875
<0x0A> 0.11065673828125
As 4.1328125
▁Med 3.40625
Cell 0.0023021697998046875
▁Th 1.0908203125
era 6.139278411865234e-05
pe 1.895427703857422e-05
ut 0.00011742115020751953
ics 0.0032558441162109375
▁prepar 2.25390625
es 0.0001049041748046875
▁to 0.471435546875
▁advance 3.66015625
▁On 1.271484375
col 0.0019435882568359375
yn 0.0005550384521484375
▁to 1.423828125
▁the 0.96044921875
▁next 0.206787109375
▁phase 0.8154296875
, 2.2890625
▁medical 7.11328125
▁communities 5.9609375
▁and 1.5439453125
▁patients 1.3125
▁are 2.9375
▁keen 4.81640625
ly 0.327392578125
▁await 0.397705078125
ing 0.003025054931640625
▁further 1.296875
▁data 2.095703125
. 2.0703125
▁The 2.236328125
▁event 7.0
ual 0.018096923828125
▁success 2.59765625
▁or 2.09375
▁failure 0.005886077880859375
▁of 0.022186279296875
▁On 1.498046875
col 0.0029964447021484375
yn 0.0009975433349609375
▁will 0.9921875
▁und 3.19921875
ou 0.0172576904296875
bt 5.698204040527344e-05
edly 0.0004634857177734375
▁have 1.0947265625
▁prof 3.931640625
ound 7.736682891845703e-05
▁consequences 3.15234375
▁for 0.471923828125
▁future 5.74609375
▁cancer 0.7490234375
▁treat 0.83984375
ments 3.147125244140625e-05
, 1.3046875
▁the 6.21875
▁lives 2.68359375
▁of 0.0102081298828125
▁count 4.171875
less 2.6226043701171875e-05
▁patients 0.2314453125
, 0.306640625
▁and 0.01067352294921875
▁the 0.203857421875
▁rapidly 7.8984375
▁evol 1.1650390625
ving 5.626678466796875e-05
▁field 1.828125
▁of 0.0039043426513671875
▁bi 2.439453125
ote 0.1614990234375
chn 0.0518798828125
ology 0.007598876953125
▁as 3.9765625
▁a 0.039794921875
▁whole 0.0015344619750976562
. 0.017120361328125
